Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites: an Interim Analysis
详细信息 查看全文
- 作者：Naminatsu Takahara (1)
Hiroyuki Isayama (1)
Yousuke Nakai (1)
Takashi Sasaki (1)
Hironori Ishigami (2) (3)
Hiroharu Yamashita (3)
Hironori Yamaguchi (3)
Tsuyoshi Hamada (1)
Rie Uchino (1)
Suguru Mizuno (1)
Koji Miyabayashi (1)
Dai Mohri (1)
Kazumichi Kawakubo (1)
Hirofumi Kogure (1)
Natsuyo Yamamoto (1)
Naoki Sasahira (1)
Kenji Hirano (1)
Hideaki Ijichi (1)
Keisuke Tateishi (1)
Minoru Tada (1)
Joji Kitayama (3)
Toshiaki Watanabe (3)
Kazuhiko Koike (1) - 关键词：Pancreatic cancer ; Malignant ascites ; S ; 1 ; Paclitaxel ; Intraperitoneal chemotherapy
- 刊名：Journal of Gastrointestinal Cancer
- 出版年：2014
- 出版时间：September 2014
- 年：2014
- 卷：45
- 期：3
- 页码：307-311
- 全文大小：348 KB
- 参考文献：1. DeWitt J, Yu M, Al-Haddad MA, Sherman S, McHenry L, Leblanc JK. Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointest Endosc. 2010;71:260-. CrossRef
2. Morizane C, Okusaka T, Morita S, et al. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas. 2011;40:415-1. CrossRef
3. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-5. CrossRef
4. Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-3.
5. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676-1. CrossRef
6. Kobayashi M, Sakamoto J, Namikawa T, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12:1412-.
7. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-3. CrossRef
8. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol. 1998;16:2620-.
9. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67-0. CrossRef
10. Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs. 2000;11:635-. CrossRef
11. Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:529-3. CrossRef
12. Schultheis B, Strumberg D, Bergmann L, et al. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Investig New Drugs. 2011;30(3):1184-2. CrossRef
13. Nakai Y, Isayama H, Sasaki T, et al. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 2010;40:774-0. CrossRef
14. Ishigami H, Kitayama J, Otani K, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76:311-. CrossRef
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-7. CrossRef
16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer. 1998;1:10-4. CrossRef
17. Shukuya T, Yasui H, Boku N, et al. Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol. 2010;40:1135-. CrossRef
18. Gamblin TC, Egorin MJ, Zuhowski EG, et al. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2008;62:647-3. CrossRef - 作者单位：Naminatsu Takahara (1)
Hiroyuki Isayama (1)
Yousuke Nakai (1)
Takashi Sasaki (1)
Hironori Ishigami (2) (3)
Hiroharu Yamashita (3)
Hironori Yamaguchi (3)
Tsuyoshi Hamada (1)
Rie Uchino (1)
Suguru Mizuno (1)
Koji Miyabayashi (1)
Dai Mohri (1)
Kazumichi Kawakubo (1)
Hirofumi Kogure (1)
Natsuyo Yamamoto (1)
Naoki Sasahira (1)
Kenji Hirano (1)
Hideaki Ijichi (1)
Keisuke Tateishi (1)
Minoru Tada (1)
Joji Kitayama (3)
Toshiaki Watanabe (3)
Kazuhiko Koike (1)
1. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo,, Bunkyo-ku, Tokyo, 113-8655, Japan
2. Department of Outpatient Chemotherapy, The University of Tokyo, Tokyo, Japan
3. Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan - ISSN：1941-6636
文摘
Objectives Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites. Methods Paclitaxel was administered intravenously at 50?mg/m2 and intraperitoneally at 20?mg/m2 on days 1 and 8 every 3?weeks, and S-1 was administered at 80?mg/m2/day for 14 consecutive days, followed by 7-day rest. Results Between April 2011 and February 2012, ten patients were enrolled. A partial response was achieved in two patients (20?%) and a disease control rate of 50?%. The median time to progression and overall survival were 2.1 and 3.4?months, respectively. Malignant ascites was completely resolved in two patients (20?%). Major grade 3/4 adverse events were myelosuppression including neutropenia (50?%) and catheter-related infection (10?%). Conclusions This novel combination chemotherapy was feasible and showed promising results in pancreatic cancer patients with malignant ascites (clinical trial registration number: UMIN000005306).